TY - JOUR
T1 - Pralatrexate in relapsed/refractory T-cell lymphoma
T2 - a retrospective multicenter study
AU - Bhurani, Mansi
AU - Admojo, Lorenz
AU - Van Der Weyden, Carrie
AU - Twigger, Robert
AU - Bazargan, Ali
AU - Quach, Hang
AU - Zimet, Allan
AU - Coyle, Luke
AU - Lindsay, Julian
AU - Radeski, Dejan
AU - Hawkes, Eliza
AU - Kennedy, Glen
AU - Irving, Ian
AU - Gutta, Naadir
AU - Trotman, Judith
AU - Yeung, James
AU - Dunlop, Lindsay
AU - Hua, Minh
AU - Giri, Pratyush
AU - Yuen, Sam
AU - Panicker, Shyam
AU - Moreton, Susan
AU - Khoo, Liane
AU - Scott, Ashleigh
AU - Kipp, David
AU - McQuillan, Andrew
AU - McCormack, Chris
AU - Dickinson, Michael
AU - Prince, Henry Miles
PY - 2021/1/28
Y1 - 2021/1/28
N2 - We present a retrospective multicenter study of pralatrexate treatment outcomes in an Australian practice setting for patients with relapsed/refractory T-cell lymphoma who had failed 1+ systemic therapies, treated via a compassionate access program. Endpoints assessed included response rates, toxicities, and subsequent therapies. Progression-free survival (PFS), time to next treatment (TTNT), event-free survival (EFS), overall survival (OS), and time to best response, were assessed by Kaplan–Meier analysis. The study included 31 patients, with median age 69 years. We demonstrated ORR of 35.5% (n = 11), including 4 complete responses (13%) and 7 partial responses (23%). The predicted median OS was 10 months, with EFS of 9 months, and PFS of 9 months. Median TTNT was 8 months. Mucositis was the most commonly observed toxicity. This study–the second largest real-world cohort reported to date–underscores the importance of pralatrexate in relapsed/refractory T-cell lymphoma, as well as its acceptable toxicity profile.
AB - We present a retrospective multicenter study of pralatrexate treatment outcomes in an Australian practice setting for patients with relapsed/refractory T-cell lymphoma who had failed 1+ systemic therapies, treated via a compassionate access program. Endpoints assessed included response rates, toxicities, and subsequent therapies. Progression-free survival (PFS), time to next treatment (TTNT), event-free survival (EFS), overall survival (OS), and time to best response, were assessed by Kaplan–Meier analysis. The study included 31 patients, with median age 69 years. We demonstrated ORR of 35.5% (n = 11), including 4 complete responses (13%) and 7 partial responses (23%). The predicted median OS was 10 months, with EFS of 9 months, and PFS of 9 months. Median TTNT was 8 months. Mucositis was the most commonly observed toxicity. This study–the second largest real-world cohort reported to date–underscores the importance of pralatrexate in relapsed/refractory T-cell lymphoma, as well as its acceptable toxicity profile.
KW - cutaneous T-cell lymphoma
KW - mucositis
KW - peripheral T-cell lymphoma
KW - Pralatrexate
KW - T-cell lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85092404863&partnerID=8YFLogxK
U2 - 10.1080/10428194.2020.1827241
DO - 10.1080/10428194.2020.1827241
M3 - Article
C2 - 33026266
AN - SCOPUS:85092404863
SN - 1042-8194
VL - 62
SP - 330
EP - 336
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 2
ER -
